Jonathan Chung‐Fai Leung, Thomson Chi‐Wang Loong, Jeremy Lok Wei, Grace Lai‐Hung Wong, Anthony Wing‐Hung Chan, Paul Cheung‐Lung Choi, Sally She‐Ting Shu, Angel Mei‐Ling Chim, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong – 23 June 2016 – Although nonalcoholic fatty liver disease (NAFLD) is closely linked to obesity, around 10%‐20% of nonobese Americans and Asians still develop NAFLD. Data on this special group are limited. We therefore studied the severity and clinical outcomes of nonobese NAFLD patients. Consecutive NAFLD patients who underwent liver biopsy were prospectively recruited.

Hao Zhang, Zheng Xing, Saravana Kumar Kailasam Mani, Brigitte Bancel, David Durantel, Fabien Zoulim, Elizabeth J. Tran, Philippe Merle, Ourania Andrisani – 23 June 2016 – Chronic hepatitis B virus (HBV) infection is a major factor in hepatocellular carcinoma (HCC) pathogenesis by a mechanism not yet understood. Elucidating mechanisms of HBV‐mediated hepatocarcinogenesis is needed to gain insights into classification and treatment of HCC.

Erin K. Spengler, David E. Kleiner, Robert J. Fontana – 23 June 2016 – Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table ).

Richard A. Rosencrantz, Tiangui Huang, Pierre‐Yves Sonke, Deepali Tewari, Praveen N. Chander – 23 June 2016

Dae Joong Kang, Naga S. Betrapally, Siddhartha A. Ghosh, R. Balfour Sartor, Phillip B. Hylemon, Patrick M. Gillevet, Arun J. Sanyal, Douglas M. Heuman, Daniel Carl, Huiping Zhou, Runping Liu, Xiang Wang, Jing Yang, Chunhua Jiao, Jeremy Herzog, H. Robert Lippman, Masoumeh Sikaroodi, Robert R. Brown, Jasmohan S. Bajaj – 23 June 2016 – The mechanisms behind the development of hepatic encephalopathy (HE) are unclear, although hyperammonemia and systemic inflammation through gut dysbiosis have been proposed.

Erin K. Spengler, David E. Kleiner, Robert J. Fontana – 23 June 2016 – Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table ).

Ki Tae Suk, Jung‐Hwan Yoon, Moon Young Kim, Chang Wook Kim, Ja Kyung Kim, Hana Park, Seong Gyu Hwang, Dong Joon Kim, Byung Seok Lee, Sae Hwan Lee, Hong Soo Kim, Jae Young Jang, Chang‐Hyeong Lee, Byung Seok Kim, Yoon Ok Jang, Mee Yon Cho, Eun Sun Jung, Yong Man Kim, Si Hyun Bae, Soon Koo Baik – 23 June 2016 – Bone marrow‐derived mesenchymal stem cell (BM‐MSC) transplantation has been suggested as an effective therapy for liver cirrhosis. The efficacy and safety of autologous BM‐MSC transplantation in the treatment of alcoholic cirrhosis were investigated.

Mikel Gastaca, Mikel Guerra, Patricia Ruiz, Alberto Ventoso, Andrés Valdivieso, Jorge Ortiz de Urbina – 23 June 2016

Jean‐François Dufour – 22 June 2016

22 June 2016